ATR and ovarian cancer: This finding is consistentwith an up-regulated ATR pathway activation resistance mechanism reportedby Kim et al. in ovarian cancer cell lines with acquired PARPi-resistance.45 Examining the effectiveness of the newly identifieddrug combinations in MDA-MB-231R cells, clonogenic survival assaysshow that the combination of low-dose Curcumin, 8, or 10 (1 μM) alongside a concentration gradient of Olaparib(0.1–100 μM) retains the ability to inhibit colony formationin a similar manner to the parental MDA-MB-231 cells (Figure 4b).